Tau-targeted therapy in Alzheimer's disease: History and current state
A Jurcau, VS Nunkoo - Frontiers in Clinical Drug Research, 2021 - books.google.com
The two main histopathological hallmarks still required for the diagnosis of Alzheimer's
disease are the presence of amyloid plaques and intraneuronal neurofibrillary tangles …
disease are the presence of amyloid plaques and intraneuronal neurofibrillary tangles …
[PDF][PDF] Tau-targeting therapy in Alzheimer's disease: Critical advances and future opportunities
Y Guo, S Li, LH Zeng, J Tan - Ageing Neurodegener. Dis, 2022 - f.oaes.cc
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by two
pathological hallmark lesions: extracellular plaques composed of β-amyloid (Aβ) peptide …
pathological hallmark lesions: extracellular plaques composed of β-amyloid (Aβ) peptide …
Tau-targeting therapies for Alzheimer disease
EE Congdon, EM Sigurdsson - Nature Reviews Neurology, 2018 - nature.com
Alzheimer disease (AD) is the most common form of dementia. Pathologically, AD is
characterized by amyloid plaques and neurofibrillary tangles in the brain, with associated …
characterized by amyloid plaques and neurofibrillary tangles in the brain, with associated …
An overview on the clinical development of tau-based therapeutics
M Medina - International journal of molecular sciences, 2018 - mdpi.com
Tauopathies such as Alzheimer's disease (AD), frontotemporal lobar degeneration, or
progressive supranuclear palsy constitute a group of brain disorders defined by …
progressive supranuclear palsy constitute a group of brain disorders defined by …
Tau-based therapies for Alzheimer's disease: Promising novel neuroprotective approaches
CL Sayas - … in Autism, Schizophrenia and Alzheimer's Disease, 2020 - Elsevier
Tau neurofibrillary tangles and amyloid-β plaques are the two main hallmarks of Alzheimer's
disease (AD). In AD, tau undergoes conformational changes and subsequent seeding …
disease (AD). In AD, tau undergoes conformational changes and subsequent seeding …
Tau biology and tau-directed therapies for Alzheimer's disease
L Bakota, R Brandt - Drugs, 2016 - Springer
Alzheimer's disease (AD) is characterised by a progressive loss of cognitive functions.
Histopathologically, AD is defined by the presence of extracellular amyloid plaques …
Histopathologically, AD is defined by the presence of extracellular amyloid plaques …
Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies
KR Brunden, JQ Trojanowski, VMY Lee - Nature reviews Drug …, 2009 - nature.com
Neuronal inclusions comprised of the microtubule-associated protein tau are found in
numerous neurodegenerative diseases, commonly known as tauopathies. In Alzheimer's …
numerous neurodegenerative diseases, commonly known as tauopathies. In Alzheimer's …
Targeting tau in Alzheimer's disease: from mechanisms to clinical therapy
J Ye, H Wan, S Chen, GP Liu - Neural Regeneration Research, 2024 - journals.lww.com
Alzheimer's disease is the most prevalent neurodegenerative disease affecting older adults.
Primary features of Alzheimer's disease include extracellular aggregation of amyloid-β …
Primary features of Alzheimer's disease include extracellular aggregation of amyloid-β …
Targeting tau protein in Alzheimer's disease
CX Gong, I Grundke-Iqbal, K Iqbal - Drugs & aging, 2010 - Springer
Alzheimer's disease (AD) is characterized histopathologically by numerous neurons with
neurofibrillary tangles and neuritic (senile) amyloid-β (Aβ) plaques, and clinically by …
neurofibrillary tangles and neuritic (senile) amyloid-β (Aβ) plaques, and clinically by …
Tau-targeting therapies for Alzheimer disease: current status and future directions
Alzheimer disease (AD) is the most common cause of dementia in older individuals. AD is
characterized pathologically by amyloid-β (Aβ) plaques and tau neurofibrillary tangles in the …
characterized pathologically by amyloid-β (Aβ) plaques and tau neurofibrillary tangles in the …